Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ching-Liang Ho

Showing results (151-160 of 157) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 157 results.
Cancer|August 20, 2021
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 studyJames J Harding, Tsai-Sheng Yang, Yen-Yang Chen, et al.
Experimental and Therapeutic Medicine|April 6, 2026
A nomogram for predicting recurrence-free survival in patients with high-risk GIST receiving adjuvant imatinib: A nationwide registry studyChun-Nan Yeh, Yan-Shen Shan, Ching-Yao Yang, et al.
BMC Cancer|July 11, 2024
Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: a nationwide registry studyHui-Jen Tsai, Yan-Shen Shan, Ching-Yao Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 11, 2015
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I MutationsChao-Hua Chiu, Cheng-Ta Yang, Jin-Yuan Shih, et al.
JTO Clinical and Research Reports|January 29, 2025
Durvalumab, Tremelimumab, and Platinum Chemotherapy in <i>EGFR</i> Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)Chee Khoon Lee, Bin-Chi Liao, Shalini Subramaniam, et al.
Targeted Oncology|January 12, 2022
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in ChinaHai-Yan Tu, Jifeng Feng, Meiqi Shi, et al.
Cancers|April 3, 2021
High-Grade B-Cell Lymphoma (HGBL) with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in TaiwanCheng-Chih Tsai, Yung-Cheng Su, Oluwaseun Adebayo Bamodu, et al.
Pageof 16

Showing results (151-160 of 157) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 157 results.
Cancer|August 20, 2021
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 studyJames J Harding, Tsai-Sheng Yang, Yen-Yang Chen, et al.
Experimental and Therapeutic Medicine|April 6, 2026
A nomogram for predicting recurrence-free survival in patients with high-risk GIST receiving adjuvant imatinib: A nationwide registry studyChun-Nan Yeh, Yan-Shen Shan, Ching-Yao Yang, et al.
BMC Cancer|July 11, 2024
Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: a nationwide registry studyHui-Jen Tsai, Yan-Shen Shan, Ching-Yao Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 11, 2015
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I MutationsChao-Hua Chiu, Cheng-Ta Yang, Jin-Yuan Shih, et al.
JTO Clinical and Research Reports|January 29, 2025
Durvalumab, Tremelimumab, and Platinum Chemotherapy in <i>EGFR</i> Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)Chee Khoon Lee, Bin-Chi Liao, Shalini Subramaniam, et al.
Targeted Oncology|January 12, 2022
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in ChinaHai-Yan Tu, Jifeng Feng, Meiqi Shi, et al.
Cancers|April 3, 2021
High-Grade B-Cell Lymphoma (HGBL) with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in TaiwanCheng-Chih Tsai, Yung-Cheng Su, Oluwaseun Adebayo Bamodu, et al.
Pageof 16